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The use of fluoroquinolones has increased in neutropenic
cancer patients over the past two decades. With respect to
empiric treatment of fever in neutropenic patients, the poor
activity of older quinolones against gram-positive cocci
prompted physicians to add specific anti-gram-positive
agents to provide better activity against streptococci, which
are frequently isolated from these patients. The efficacy and
safety of oral antibiotic regimens that include fluoroquino-
lones for the treatment of low-risk febrile neutropenic
patients have been documented in two large studies [1, 2].
The widespread use of fluoroquinolones as prophylactic
agents in cancer patients has been associated with the
occurrence of resistance in E. coli and coagulase-negative
staphylococci, organisms which are most often responsible
for bacteremia in these patients [3].
Moxifloxacin is an 8-methoxyquinolone that has en-
hanced activity against gram-positive bacteria relative to
ciprofloxacin and other older fluoroquinolones. Oral moxi-
floxacin is 90% bioavailable, and its mean half-life of 12 h
allows once-a-day dosing. Peak serum concentrations of
3.2–4.5 μg/ml have been achieved following oral doses of
400 mg of moxifloxacin, and the agent is widely distributed
throughout the body [4]. The aim of the present study was
to assess the in vitro activity of moxifloxacin against gram-
positive and gram-negative bacteria isolated from the blood
of neutropenic cancer patients and to compare it with other
fluoroquinolones and reference antibiotics.
The collection of bacterial strains isolated from the blood
of febrile neutropenic cancer patients randomized in two trials
conducted by the Infectious Diseases Group of the European
Organization for Research and Treatment of Cancer
(EORTC-IDG) between 1993 and 2000 [5, 6] yielded 152
gram-positive isolates, including 71 coagulase-negative
staphylococci, 29 S. aureus, 19 S. mitis, 19 S. oralis, and
14 E. faecalis, and 85 gram-negative strains, including 44 E.
coli, 30 K. pneumoniae and 11 P. aeruginosa. These strains
were used in the present study. Bacterial identification was
confirmed at the Microbiological Reference Center (CHUV,
Lausanne) using standardized methods [7].
Minimal inhibitory concentrations (MICs) of four fluo-
roquinolones (moxifloxacin, levofloxacin, gatifloxacin,
ciprofloxacin), as well as cefepime, meropenem, amikacin,
vancomycin, penicillin for streptococci and oxacillin for
staphylococci were determined using a microbroth dilution
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Table 1 In vitro activity of moxifloxacin and comparative agents against gram-positive and gram-negative bacteria
Organism Antibiotic MIC50 (μg/ml) MIC90 (μg/ml) Range (μg/ml) Susceptible (%)
CNS (n=71) Moxifloxacin 1 2 0.016–16 45
Levofloxacin 2 8 0.016–>64 42
Gatifloxacin 2 4 0.032–16 45
Ciprofloxacin 8 64 0.016–>64 42
Oxacillin 4 >64 0.016–>64 49
Cefepime 8 64 0.016–>64 54
Meropenem 4 32 0.016–>64 51
Vancomycin 2 2 0.125–>64 96
S. aureus (n=29) Moxifloxacin 0.064 0.125 0.016–64 90
Levofloxacin 0.125 0.25 0.064–32 90
Gatifloxacin 0.032 0.125 0.032–32 90
Ciprofloxacin 0.25 1 0.125–16 90
Oxacillin 0.5 1 0.125–>64 90
Cefepime 4 4 2–>64 90
Meropenem 0.125 0.5 0.016–32 90
Vancomycin 1 1 0.125–1 100
S. oralis (n=20) Moxifloxacin 0.25 0.5 0.125–16 90
Levofloxacin 1 2 0.125–64 90
Gatifloxacin 0.5 2 0.25–32 79
Ciprofloxacin 2 8 0.016–32 75
Penicillin G 0.016 0.064 0.016–0.25 95
Cefepime 0.25 0.5 0.016–2 95
Meropenem 0.016 0.016 0.016–0.5 100
Vancomycin 0.25 0.5 0.016–0.5 100
S. mitis (n=19) Moxifloxacin 0.25 0.5 0.064–8 95
Levofloxacin 1 2 0.125–32 95
Gatifloxacin 0.5 2 0.125–16 90
Ciprofloxacin 1 16 0.016–16 63
Penicillin G 0.016 0.5 0.016–64 84
Cefepime 0.064 1 0.016–2 78
Meropenem 0.016 0.25 0.016–1 95
Vancomycin 0.25 0.25 0.016–0.5 100
E. faecalis (n=14) Moxifloxacin 0.5 8 0.125–32 71
Levofloxacin 2 64 0.25–>64 79
Gatifloxacin 1 16 0.125–32 64
Ciprofloxacin 2 32 0.25–>64 33
Penicillin G 2 4 0.25–8 100
Meropenem 4 8 1–16 87
Vancomycin 1 2 0.5–2 100
Amikacin 1 2 0.5–2 –
E. coli (n=44) Moxifloxacin 0.016 16 0.016–32 80
Levofloxacin 0.016 8 0.016–64 80
Gatifloxacin 0.032 8 0.032–32 80
Ciprofloxacin 0.016 16 0.016–>64 80
Ceftazidime 0.25 0.5 0.064–32 98
Cefepime 0.25 2 0.064–8 100
Meropenem 0.064 0.25 0.016–0.5 100
Amikacin 4 8 1–8 100
K. pneumoniae (n=30) Moxifloxacin 0.064 0.125 0.064–0.25 100
Levofloxacin 0.064 0.064 0.016–0.125 100
Gatifloxacin 0.032 0.032 0.032–0.125 100
Ciprofloxacin 0.016 0.016 0.016–0.064 100
Ceftazidime 0.25 8 0.125–64 96
Cefepime 0.125 4 0.016–8 100
Meropenem 0.25 0.5 0.016–0.5 100
Amikacin 2 4 1–16 100
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technique according to methods recommended by the
Clinical and Laboratory Standards Institute (CLSI) [8].
For all antibiotics tested, the MIC breakpoints recommen-
ded by the CLSI were used. Since CLSI did not provide
MIC breakpoints for moxifloxacin against any organisms
other than staphylococci (<0.5 μg/ml for susceptibility), the
MIC breakpoints used for moxifloxacin against all other
organisms were <1 μg/ml for susceptibility, >2 μg/ml for
resistance [9]. Quality control was performed by testing
American Type Culture Collection (ATCC) strains E. coli
25922 and 35218, S. aureus 29213, E. faecalis 29212 and
P. aeruginosa 27853.
Moxifloxacin displayed excellent in vitro activity against
staphylococci and viridans streptococci, and compared with
all other quinolones, it had the lowest MIC90 against
coagulase-negative staphylococci, S. aureus, S. oralis and
S. mitis (Table 1). The better activity against viridans
streptococci is particularly interesting, and might reduce the
need to add a beta-lactam for the oral treatment of fever in
low-risk neutropenic patients. Compared with ciprofloxa-
cin, moxifloxacin exhibits increased, but still only relatively
modest activity against enterococci.
Against E. coli, the MIC90 of all fluoroquinolones tested
was between 8 and 16 μg/ml: 9 of 44 isolates were highly
resistant. These highly resistant organisms were isolated
from nine patients hospitalized in six different centers. Six
of the nine patients with fluoroquinolone-resistant E. coli
had received quinolone prophylaxis before the occurrence
of the bacteremic episode. In contrast, none of 35 patients
infected with fluoroquinolone-susceptible E. coli strains
had received fluoroquinolone prophylaxis (Fisher’s test
p<0.001). Thus, as previously described in EORTC-IDG
trials, infections due to fluoroquinolone-resistant E. coli
still occur in high-risk patients who receive fluoroquinolone
prophylaxis, even though its use decreased from 52% in the
trial performed over 1993–1994 [5] to 33% in the trial
performed over 1997–2000 [6]. Regarding other gram-
negative isolates, moxifloxacin is highly active against
Klebsiella spp and was less active than ciprofloxacin
against P. aeruginosa.
Rolston et al. [10] tested the in vitro activity of
moxifloxacin against 900 strains isolated from cancer
patients: two thirds of these strains were bloodstream
isolates. As in the present study, moxifloxacin was the most
active fluoroquinolone against coagulase-negative staphylo-
cocci, S. aureus and viridans streptococci. These researchers
also reported fluoroquinolone-resistant E. coli related to
previous prophylaxis and lower in vitro activity of moxi-
floxacin against P. aeruginosa compared with ciprofloxacin.
The susceptibility of the EORTC-IDG strains to various
antibiotics commonly used in neutropenic patients has been
tested. As shown for bacteria isolated from neutropenic
patients in US cancer centers [11], the highest rates of
susceptibility were observed with cefepime and merope-
nem, which are active against 100% of viridans streptococ-
ci, E. coli and Klebsiella spp. Amikacin is active against all
gram-negative bacteria including P. aeruginosa, and cefta-
zidime is active against the vast majority of E. coli,
Klebsiella spp and P. aeruginosa.
In conclusion, this study confirms that moxifloxacin
exhibits increased in vitro activity relative to older
fluoroquinolones against gram-positive bacteria isolated
from the blood of neutropenic patients. In areas with low
fluoroquinolone resistance among Enterobacteriaceae, these
findings could support the use of single-drug oral regimens
in low-risk febrile neutropenic patients. This in turn might
provide a potential benefit in terms of compliance,
especially for outpatients. Although the moderate in vitro
activity of moxifloxacin against P. aeruginosa might be a
potential problem, this non-fermentative bacteria is current-
ly isolated only infrequently from the blood of low-risk
neutropenic cancer patients. Since the emergence of
resistant E. coli was observed in patients receiving
fluoroquinolone prophylaxis, this practice should be
avoided in low-risk neutropenic patients as it might limit
the use of fluoroquinolones as oral therapeutic agents.
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Table 1 (continued)
Organism Antibiotic MIC50 (μg/ml) MIC90 (μg/ml) Range (μg/ml) Susceptible (%)
P. aeruginosa (n=11) Moxifloxacin 1 64 0.25–64 64
Levofloxacin 0.25 16 0.25–64 82
Gatifloxacin 0.5 32 0.25–32 82
Ciprofloxacin 0.125 8 0.016–32 82
Ceftazidime 2 128 2–128 82
Cefepime 4 128 2–128 73
Meropenem 2 8 1–64 64
Amikacin 1 8 0.5–16 100
CNS coagulase-negative staphylococci
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